Experimental and Clinical Basis for the Use of Statins in Patients With Ischemic and Nonischemic Cardiomyopathy

Kumudha Ramasubbu, Jerry Estep, Donna L. White, Anita Deswal, Douglas L. Mann

Research output: Contribution to journalReview articlepeer-review

136 Scopus citations

Abstract

Over the past 2 decades our understanding of the pathologic mechanisms that lead to heart failure (HF) has evolved from simplistic hemodynamic models to more complex models that have implicated neurohormonal activation and adverse cardiac remodeling as important mechanisms of disease progression. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have become a standard part of the armamentarium in the prevention and treatment of coronary artery disease. Apart from their lipid-lowering capabilities, statins seem to have non-lipid-lowering effects that impact neurohormonal activation and cardiac remodeling. This review will examine the potential benefits of statins in HF patients with ischemic and nonischemic cardiomyopathy as well as potential concerns regarding the use of statins in these patients.

Original languageEnglish
Pages (from-to)415-426
Number of pages12
JournalJournal of the American College of Cardiology
Volume51
Issue number4
DOIs
StatePublished - Jan 29 2008
Externally publishedYes

Fingerprint Dive into the research topics of 'Experimental and Clinical Basis for the Use of Statins in Patients With Ischemic and Nonischemic Cardiomyopathy'. Together they form a unique fingerprint.

Cite this